| HRTX Stock | | | USD 1.69 0.07 3.98% |
Director
Mr. John W. Poyhonen is Independent Director of Heron Therapeutics, Inc. Mr. Poyhonen has more than 25 years of experience serving in leadership positions in biotechnology, pharmaceutical and food ingredient companies and commercializing innovative products. From 2014 through its acquisition by Firmenich, Inc. in November 2018, Mr. Poyhonen was the President, Chief Executive Officer and a director of Senomyx, Inc. He joined Senomyx, Inc. in 2003 as Vice President and Chief Business Officer was promoted in 2004 to Vice President and Chief Financial and Business Officer was named Senior Vice President, Chief Financial and Business Officer in 2006 was promoted to President and Chief Operating Officer in 2009 and promoted to President and Chief Executive Officer in 2014. From 1996 to 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., most recently as Vice President of National Sales. Prior to holding this position, Mr. Poyhonen served as Vice President of Marketing and Vice President of National Accounts. He was previously a director of Ardea Biosciences, Inc. from 2007 through its acquisition by AstraZeneca PLC in 2012 since 2014.
| Age | 64 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Address | 4242 Campus Point Court, San Diego, CA, United States, 92121 |
| Phone | 858 251 4400 |
| Web | https://www.herontx.com |
Poyhonen received a B.A. degree in marketing from Michigan State University and a M.B.A. degree from the University of Kansas.
Heron Therapeuti Management Efficiency
The company has return on total asset
(ROA) of
(0.0231) % which means that it has lost $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Equity is likely to rise to 3.42 in 2024, whereas
Return On Tangible Assets are likely to drop
(0.52) in 2024. At this time, Heron Therapeuti's
Total Assets are fairly stable compared to the past year.
Non Current Assets Total is likely to rise to about 35.4
M in 2024, whereas
Other Current Assets are likely to drop slightly above 5.5
M in 2024.
Heron Therapeuti currently holds 179.63
M in liabilities with Debt to Equity
(D/E) ratio of 6.64, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Heron Therapeuti has a current ratio of 1.73, which is within standard range for the sector. Note, when we think about Heron Therapeuti's use of debt, we should always consider it together with its cash and equity.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Heron Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people. Heron Therapeuti (HRTX) is traded on NASDAQ Exchange in USA. It is located in 4242 Campus Point Court, San Diego, CA, United States, 92121 and employs 126 people. Heron Therapeuti is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Heron Therapeuti Leadership Team
Elected by the shareholders, the Heron Therapeuti's board of directors comprises two types of representatives: Heron Therapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heron. The board's role is to monitor Heron Therapeuti's management team and ensure that shareholders' interests are well served. Heron Therapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heron Therapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Executive Officer | |
| Barry PharmD, Chairman CEO | |
| Lisa Peraza, VP Officer | |
| Chris Storgard, Chief Officer | |
| Kimberly Manhard, Independent Director | |
| Sean Ristine, Vice President - Human Resources | |
| Michael Mathews, Senior Vice President - Pain Franchise | |
| John Poyhonen, Independent Director | |
| Thomas Ottoboni, Senior Vice President - Pharmaceutical and Preclinical Research and Development | |
| Brett Fleshman, Chief Officer | |
| David Szekeres, Senior Vice President General Counsel, Business Development, Corporate Secretary | |
| Ira Duarte, Executive CFO | |
| Ryan Craig, Vice Marketing | |
| Craig Collard, CEO Director | |
| Jeff Cohn, Assistant Director | |
| Robert Sullivan, Senior Operations | |
Heron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heron Therapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to
measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to
predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.